Reference is made to the extraordinary general meeting in Lifecare ASA (the
"Company") held on 17 September 2024, where it was resolved to carry out a
share consolidation (reverse split) in the ratio of 13:1.

The share consolidation has now been registered with the Norwegian Register of
Business Enterprises, and the Company's share capital is NOK 78,112,907.60
(unchanged) divided on 15,021,713 shares, each with a nominal value of NOK
5.20.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")
on the sensor body for read-out of pressure variations. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-09-30 17:31 CEST.